JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Biogen7,726 enrolled

Overview

The objective of the study is to estimate the prevalence of anti-JCV antibodies in multiple sclerosis (MS) participants.

This is a cross-sectional, multi-center, multi-national, epidemiological study to estimate the prevalence of anti-JCV antibody in MS participants. This study will provide an estimate of the prevalence of anti-JCV antibody in the MS population and will investigate inter-country differences.

Study Type

OBSERVATIONAL

Enrollment

7,726

Conditions

Multiple Sclerosis

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Key Inclusion Criteria: * All candidates for this study must have the ability to understand the purpose of the study and provide signed and dated informed consent. * All patients with a diagnosis of Multiple Sclerosis (MS) of any type, irrespective of their treatment, are eligible to participate once. Key Exclusion Criteria: * None NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Outcomes

Primary Outcomes

Prevalence of anti-JCV antibodies

Prevalence of anti-JCV antibodies will be estimated as the number of participants with anti-JCV antibodies detected in serum divided by the total number of participants with a serum sample that was evaluated.

Time frame: Single timepoint (Day 1)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.